Theodoraki et al. has investigated whether the level of tumor-derived or T cell-derived PD-L1-positive sEVs can predict clinical outcomes of HNSCC patients (n = 18) treated with a combination of cetuximab, ipilimumab, and radiation therapy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.